Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial

Medicine and Dentistry

• Inpatient 100%
• Diuretic Agent 83%
• Canagliflozin 83%
• Plasma 66%
• Heart Failure 66%
• Patient with Type 2 Diabetes 50%
• Sodium Glucose Cotransporter 2 Inhibitor 50%
• Patient 33%
• Kidney Function 33%
• Electrolyte 33%
• Diuretic Therapy 33%
• Therapeutic Procedure 16%
• Phenotype 16%
• Mortality Rate 16%
• Uric Acid 16%
• Serum 16%
• Heart Failure 16%
• Amino Terminal Sequence 16%
• New York Heart Association Class 16%
• Furosemide 16%
• Hyperuricemia 16%
• Brain Natriuretic Peptide 16%
• Osmotic Diuresis 16%
• Glimepiride 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Diuretic Agent 83%
• Canagliflozin 83%
• Heart Failure 66%
• Heart Failure with Preserved Ejection Fraction 50%
• Sodium Glucose Cotransporter 2 Inhibitor 50%
• Mortality Rate 16%
• Prognosis 16%
• Uric Acid 16%
• Brain Natriuretic Peptide 16%
• Furosemide 16%
• Hyperuricemia 16%
• Glimepiride 16%